February 17th, 2025 “EURETINA-Brief”© Issue No. 310
Dear EURETINA Members, A very warm welcome to the February 17th, 2025 edition of EURETINA’s web-based digital periodical, “EURETINA Brief”. EURETINA are delighted to continue…
EURETINA’s
DIGITAL
NEWSLETTER
Featured Articles
1
February 17th, 2025
Latest News
February 17th, 2025 “EURETINA-Brief”© Issue No. 310
Dear EURETINA Members, A very warm welcome to the February 17th, 2025 edition of EURETINA’s…
Research on autosomal dominant retinitis pigmentosa (adRP) has reported a novel RP1 truncating mutation, not previously reported in the literature.
Researchers at the Eye Centre, Zhejiang University School of Medicine, Hangzhou, China, have reported a…
Foundation Fighting Blindness (FFB) have presented genetic data on IRDs for almost 34,000 patients and families within international sites.
A collaboration of 41 international clinical centres that manage patients affected with inherited retinal diseases…
Ocugen Inc., receives European Medicines Agency (EMA) designation of Advanced Therapy Medicinal Product (ATMP) for “OCU400” to enter for Phase 3 for retinitis pigmentosa.
Ocugen Inc., (NASDAQ:OCGN), an ophthalmic biopharmaceutical company based in Malvern, Pennsylvania, has announced that the…